Anita Barikian
Ophthalmology · Stuart, FLNPI 1699126714
Payments from drug & device makers
Across 120 payments — averaging $87.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Regeneron$4K
- Regeneron Healthcare Solutions, Inc.$1K
- Apellis Pharmaceuticals, Inc.$932
- Alimera Sciences, Inc.$892
- Astellas Pharma US Inc$763
- Genentech USA, Inc.$648
- plus $2K from 20 others
Across 14 payments — averaging $1173.74 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Regeneron$16K
What the payments were for
- Consulting fees$3,62034%
- Travel & lodging$410%
- Food & beverage$6,86465%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Regeneron | 7 | $3,892 |
| Regeneron Healthcare Solutions, Inc. | 21 | $1,019 |
| Apellis Pharmaceuticals, Inc. | 18 | $932 |
| Alimera Sciences, Inc. | 11 | $892 |
| Astellas Pharma US Inc | 14 | $763 |
| Genentech USA, Inc. | 9 | $648 |
| AbbVie(2 entities) | 9 | $448 |
| Bausch & Lomb Americas Inc. | 6 | $352 |
| Carl Zeiss Meditec USA, Inc. | 2 | $264 |
| Alcon | 3 | $259 |
| Carl Zeiss Meditec, Inc. | 2 | $215 |
| Ocular Therapeutix, Inc. | 1 | $191 |
| Dutch Ophthalmic, USA | 2 | $184 |
| Beaver-visitec International, Inc. | 1 | $109 |
| Novartis | 1 | $52 |
| Dompe US, Inc. | 2 | $48 |
| Oyster Point Pharma, Inc. | 2 | $46 |
| Coherus Oncology, Inc. | 1 | $33 |
| Harrow Eye, LLC | 1 | $31 |
| Johnson & Johnson Surgical Vision, Inc. | 1 | $27 |
| Amgen | 1 | $27 |
| Sun Pharmaceutical Industries Inc. | 1 | $24 |
| Rayner Intraocular Lenses Limited | 1 | $23 |
| Mallinckrodt Hospital Products Inc. | 1 | $22 |
| Aerie Pharmaceuticals, Inc. | 1 | $16 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$10,525 in reported general payments places this provider in the 80th percentile of 1,405 ophthalmology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EyleaAflibercept | 65 | $147,923 |
| Eylea HdAflibercept | 31 | $107,625 |
| RestasisCyclosporine | 54 | $68,617 |
| LumiganBimatoprost | 98 | $63,197 |
| LucentisRanibizumab | 14 | $29,250 |
| RhopressaNetarsudil Mesylate | 29 | $16,742 |
| VyzultaLatanoprostene Bunod | 22 | $12,752 |
| Alphagan PBrimonidine Tartrate | 18 | $10,398 |
| CombiganBrimonidine Tartrate/Timolol | 16 | $9,743 |
| Brimonidine Tartrate | 137 | $8,697 |
| Cyclosporine | 13 | $8,368 |
| Travoprost | 34 | $5,681 |
| Latanoprost | 444 | $5,521 |
| Brinzolamide | 35 | $5,381 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 11 | $3,876 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Regeneron Healthcare Solutions, Inc.Eylea, Eylea Hd | $1,019 | $255,54896 claims |
| AbbVieRestasis, Lumigan, Alphagan P, Combigan | $448 | $151,955186 claims |
| Aerie Pharmaceuticals, Inc.Rhopressa | $16 | $16,74229 claims |
| Bausch & Lomb Americas Inc.Vyzulta | $352 | $12,75222 claims |
| AlconSimbrinza | $259 | $3,87611 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,405 ophthalmology providers in Florida.
Other ophthalmology in Stuart
- Ronald FrenkelStuart$2.1M
- David EichenbaumSt Petersburg$34.4M
- Robert RadenDelray Beach$7.8M
- Carl DanzigPompano Beach$5.3M
- Bruce SegalDelray Beach$4.7M
- Cathleen McCabeBradenton$4.6M
- Ivan SunerTampa$3.7M
- Sunir JoshiFt Lauderdale$3.7M
- Harold BrooksTallahassee$3.5M
- Matthew CunninghamOrlando$2.9M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.